简介:Geneticchangesofseveraltumorsuppressorgenessuchasp53andpl6areinvolvedinthegenesisordevelopmentofglioma.["’]Recently,anovelgenewhichencodesaproteinwithsimilaritytop53throughoutitsDNA-binding,transactivation,andoligomerizationdomains,calledp73,wasident...
简介:AbstractBackground:The hepatitis B virus X (HBx) protein plays a critical role in the initiation and progression of hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC). In the early stage of the disease, HBx facilitates tumor onset by inactivating the tumor suppressor p53. The p53-encoding gene, however, is frequently mutated or deleted as the cancer progresses to the late stage and, under such circumstance, the p53 homolog TAp63 can harness HCC growth by transactivating several important p53-target genes.Methods:To determine whether HBx regulates TAp63, we performed co-immunoprecipitation assay, real-time quantitative polymerase chain reaction, immunoblotting, and flow cytometry analysis in p53-null cancer cell lines, Hep3B and H1299.Results:HBx interacts with the transactivation domain of TAp63, as HBx was co-immunoprecipitated with TAp63 but not with ΔNp63. The interaction between HBx and TAp63 abolished transcriptional activity of TAp63, as evidenced by the reduction of the levels of its target genes p21 and PUMA, consequently leading to restricted apoptosis and augmented proliferation of HCC cells.Conclusion:HBV induces progression of HCC that harbors defective p53 by inhibiting the tumor suppressor TAp63.
简介:摘要:目的:本研究旨在评估布比卡因脂质体在腹部手术经腹部横向平面(TAP)阻滞中的应用。 方法:本研究采用随机研究设计,将腹腔镜结直肠手术后的患者随机分为两组:一组接受含地塞米松和/或肾上腺素的布比卡因脂质体TAP阻滞(实验组),另一组接受传统的局部麻醉药物TAP阻滞(对照组)。比较两组患者的术后疼痛评分、下床活动时间、肠蠕动恢复时间及住院时间等指标。结果:研究发现,加入地塞米松和/或肾上腺素的布比卡因脂质体TAP阻滞能有效延长镇痛时间,与对照组相比,在术后疼痛评分、下床活动时间、肠蠕动恢复时间及住院时间方面未显示出显著差异。然而,从经济成本的角度分析,实验组的总体成本明显低于对照组。结论:在腹腔镜结直肠手术后应用加入地塞米松和/或肾上腺素的布比卡因脂质体进行TAP阻滞是一种有效且经济的镇痛策略。虽然两组在术后疼痛管理的主要临床指标上未见明显差异,但考虑到成本效益,布比卡因脂质体TAP阻滞提供了一个具有经济优势的选择,适合在临床实践中推广应用。
简介:摘要目的探讨肝胆外科术后胆漏的治疗策略及疗效。方法回顾性分析2010年1月至2018年8月在甘肃省人民医院行肝胆外科手术后发生胆漏的73例患者临床资料。其中男35例,女38例;年龄21~75岁,中位年龄56岁。患者均签署知情同意书,符合医学伦理学规定。观察患者胆漏发生情况、治疗及疗效。结果同期行肝胆手术12 780例,胆漏发生率0.57%(73/12 780)。其中腹腔镜胆囊切除术后胆漏32例,腹腔镜胆总管探查取石术后23例,胆肠吻合术后11例,肝切除术后7例。采用双套管负压冲洗引流治疗15例,经皮经肝胆道引流术(PTCD)+超声引导下腹腔穿刺引流治疗8例,内镜下鼻胆管引流术(ENBD)治疗4例,ERCP治疗1例,均治愈。单纯性腹腔引流治疗17例,治愈13例;超声引导下腹腔穿刺引流治疗18例,治愈16例。二次手术治疗10例,治愈8例。总治愈率89%(65/73),8例未愈,其中1例死于二次手术后腹腔出血。结论肝胆外科术后胆漏发生率仍较高,应尽早判断胆漏位置和严重程度,尽可能选择微创治疗,避免盲目进行二次手术。